Apoptosis News and Research

RSS

Apoptosis is programmed cell death, the body's normal method of disposing of damaged, unwanted, or unneeded cells.

Human Genome Sciences commences patient dosing in its HGS1029 inhibitor trial

Human Genome Sciences, Inc. and Aegera Therapeutics, Inc. today announced that HGS has initiated dosing in a Phase 1 clinical trial to evaluate the safety and tolerability of its lead IAP inhibitor, HGS1029, as monotherapy in patients with advanced lymphoid tumors.

23 Nov 2009

Genta announces preliminary results from study of Genasense Injection for advanced melanoma

Genta Incorporated announced preliminary results that show a high objective response rate in a pilot study of patients with advanced melanoma that incorporates the Company’s lead oncology product, Genasense® (oblimersen sodium) Injection, administered for the first time as a 1-hour high-dose intravenous (IV) infusion.

20 Nov 2009

Aegera Therapeutics commences AEG35156 Phase 2B study for AML

Aegera Therapeutics Inc. announced today the dosing of the first patient in a randomized Phase 2B study of AEG35156, a targeted antisense therapeutic in mid-stage development for multiple oncology indications.

19 Nov 2009

Study: EP4 agonist may reduce gastric bleeding and inflammation

Over 300 million patients use non-steroidal anti-inflammatory drugs (NSAIDs) in the world to treat pain, arthritis, fever and other diseases. Nearly 30% of the users suffer from gastric lesions and bleeding.

19 Nov 2009

New data on Synta Pharmaceuticals' elesclomol presented at the AACR-NCI-EORTC Conference

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today presented new data on the mechanism of action of elesclomol, a first-in-class oxidative stress inducer, at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics in Boston, Mass.

18 Nov 2009

Data on Synta Pharmaceuticals' STA-9090 synthetic inhibitor of Hsp90 presented

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical data presented at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics shows that STA-9090, a novel, synthetic inhibitor of heat shock protein 90 (Hsp90), demonstrated strong activity in multiple tumor models.

18 Nov 2009

Cancer-fighting protein successfully placed directly into solid tumors and turned on

Experiments at the Pioneer Valley Life Sciences Institute (PVLSI) at Baystate Medical Center in Springfield, Mass., reported in a recent British Journal of Cancer, confirm that University of Massachusetts Amherst chemical engineer Neil Forbes' delivery and trigger system has for the first time successfully placed TRAIL, a cancer-fighting protein, directly into solid tumors and on cue, turned it on. The treatment improved the 30-day survival time of mice with mammary tumors from 0 to 100 percent.

18 Nov 2009

First-quarter fiscal 2010 results announced by Senesco Technologies

Senesco Technologies, Inc. today reported financial results for the three months ended September 30, 2009.

17 Nov 2009

Melanoma Institute director to present Phase 2 study data of PV-10 for metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that Professor John F. Thompson, MD, Professor of Melanoma and Surgical Oncology at the University of Sydney, Director of the Melanoma Institute Australia, and Lead Investigator of the Phase 2 study of PV-10 for Metastatic Melanoma, will be presenting data at the 3rd World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers on November 21, 2009 in Berlin, Germany.

17 Nov 2009

New insights into cells' reaction to DNA damage

Cancer researchers of the Max Delbr-ck Center for Molecular Medicine (MDC) Berlin-Buch have gained new insights into how cells react to DNA damage. Dr. Michael Stilmann, Dr. Michael Hinz and Professor Claus Scheidereit have shown that the protein PARP-1, which detects DNA damage within seconds, activates the transcription factor NF-kappaB, a well-known regulator of gene expression.

17 Nov 2009

Interim data from Hollis-Eden Pharmaceuticals' Apoptone Phase I/II clinical trial presented

Hollis-Eden Pharmaceuticals, Inc., today reported preliminary results of its ongoing Phase I/II clinical trial with Apoptone® (HE3235) for hormone-resistant prostate cancer (also called castrate-resistant prostate cancer or CRPC). Presented at the Molecular Targets and Cancer Therapeutics Conference, which is co-sponsored by the AACR, NCI and EORTC, the poster is titled: "Results of preclinical and clinical Phase I/II open-label dose-ranging trial with HE3235, a synthetic adrenal hormone, in Castrate Resistant Prostate Cancer (CRPC)."

16 Nov 2009

FDA issues a Complete Response Letter for Human Genome Sciences' raxibacumab BLA

Human Genome Sciences, Inc. today announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) relating to the Company’s Biologics License Application (BLA) requesting the approval of raxibacumab for use in the treatment of inhalational anthrax. The FDA issues Complete Response Letters to request additional information needed to complete the review of a BLA.

16 Nov 2009

Lipid that accumulates in brain cells drives cell death, says research

The lipid that accumulates in brain cells of individuals with an inherited enzyme disorder also drives the cell death that is a hallmark of the disease, according to new research led by St. Jude Children's Research Hospital investigators.

13 Nov 2009

Senesco's multiple myeloma drug candidate data to be presented at the AACR-NCI-EORTC conference

Senesco Technologies, Inc. announced today that Catherine Taylor, one of the Company's funded researchers, will be presenting pre-clinical stability and biological activity data on SNS-01, Senesco's multiple myeloma drug candidate, at the 2009 American Association for Cancer Research (AACR)-National Cancer Institute (NCI)-European Organization for Research and Treatment of Cancer (EORTC) Molecular Targets and Cancer Therapeutics Conference.

12 Nov 2009

Potential new drug for lung cancer eliminates tumors in mice

A potential new drug for lung cancer has eliminated tumours in 50% of mice in a new study published today in the journal Cancer Research. In the animals, the drug also stopped lung cancer tumours from growing and becoming resistant to treatment. The authors of the research, from Imperial College London, are now planning to take the drug into clinical trials, to establish whether it could offer hope to patients with an inoperable form of lung cancer.

11 Nov 2009

EpiCept announces third quarter 2009 financial results

EpiCept Corporation today announced operating and financial results for the three and nine months ended September 30, 2009, and provided an update on Ceplene® and several of the Company’s key product candidates.

10 Nov 2009

Health Canada accepts for review the EpiCept’s New Drug Submission for Ceplene

EpiCept Corporation today announced that Health Canada has accepted for review the Company’s New Drug Submission (NDS) for Ceplene® (histamine dihydrochloride) for the remission maintenance of acute myeloid leukemia (AML) patients in first complete remission.

9 Nov 2009

Graceway Pharmaceuticals acquires global rights to Gilead Sciences' GS 9191 anti-proliferative agent

Graceway Pharmaceuticals, LLC, a portfolio company of GTCR Golder Rauner, LLC, today announced that the company has acquired from Gilead Sciences, Inc. the worldwide license, including related regulatory filings and intellectual properties, to Gilead’s investigational molecule, GS 9191, for topical use. GS 9191 is an anti-proliferative agent that works by inhibiting cellular DNA synthesis, leading to the induction of apoptosis, or programmed cell death.

7 Nov 2009

TREANDA induces durable responses in indolent B-cell non-Hodgkin's lymphoma patients

Cephalon, Inc. today announced the journal Cancer has published a pivotal study demonstrating that TREANDA® (bendamustine HCl) for Injection induced durable responses in patients with indolent B-cell non-Hodgkin's lymphoma (NHL) whose disease had progressed during or within six months of treatment with rituximab.

6 Nov 2009

FDA grants orphan drug designation for Sunesis Pharmaceuticals' voreloxin

Sunesis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in AML: a single-agent study, known as REVEAL-1, of voreloxin in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML.

6 Nov 2009

Apoptosis News and Research

Human Genome Sciences commences patient dosing in its HGS1029 inhibitor trial

Genta announces preliminary results from study of Genasense Injection for advanced melanoma

Aegera Therapeutics commences AEG35156 Phase 2B study for AML

Study: EP4 agonist may reduce gastric bleeding and inflammation

New data on Synta Pharmaceuticals' elesclomol presented at the AACR-NCI-EORTC Conference

Data on Synta Pharmaceuticals' STA-9090 synthetic inhibitor of Hsp90 presented

Cancer-fighting protein successfully placed directly into solid tumors and turned on

First-quarter fiscal 2010 results announced by Senesco Technologies

Melanoma Institute director to present Phase 2 study data of PV-10 for metastatic melanoma

New insights into cells' reaction to DNA damage

Interim data from Hollis-Eden Pharmaceuticals' Apoptone Phase I/II clinical trial presented

FDA issues a Complete Response Letter for Human Genome Sciences' raxibacumab BLA

Lipid that accumulates in brain cells drives cell death, says research

Senesco's multiple myeloma drug candidate data to be presented at the AACR-NCI-EORTC conference

Potential new drug for lung cancer eliminates tumors in mice

EpiCept announces third quarter 2009 financial results

Health Canada accepts for review the EpiCept’s New Drug Submission for Ceplene

Graceway Pharmaceuticals acquires global rights to Gilead Sciences' GS 9191 anti-proliferative agent

TREANDA induces durable responses in indolent B-cell non-Hodgkin's lymphoma patients

FDA grants orphan drug designation for Sunesis Pharmaceuticals' voreloxin

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News